MalariaNCT00346346
Analysis of the Immune Response to the Malaria Parasite in Mali, West Africa
An observational study of Malaria, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in Mali.
Trial summary
This study will examine the immune response to the malaria parasite at the cellular level to better understand why people achieve natural immunity to the parasite only after multiple infections and why immunity diminishes rapidly in the absence of ongoing infection. Read more about this study
- Who is it for?
- Ages 2 to 25 years
- Conditions the study is for
- Malaria
- How many people
- 237 participants
- Where
- 1 siteMali
- Study dates
- 17 Apr 2006to 23 Jan 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Males and females ages 2 to 10 years or 18 to 25 years.
- Will be living in Kambila for one year and available for 12 month follow-up.
- Willing to have blood specimens stored.
- Willingness of adult volunteer to participate in the study as evidenced by the completed informed consent document.
- Willingness of parent or guardian to have his or her child participate in the study as evidenced by the completed informed consent document.
Who cannot join
- Active bleeding or hematocrit less than or equal to 15 % (for both children and adults).
- Fever greater than 38 degrees C, or systemic illness at enrollment.
- Currently using anti-malarial medications.
- The following two exclusion items may not have occurred in the last 30 days: participation in a vaccine or drug trial, or use of corticosteroid or other immunosuppressive drugs.
- Current pregnancy or a plan to become pregnant during the one year study period. Pregnancy status will be determined at enrollment by urine dipstick, and at subsequent time points by self-report only.
- While on this protocol, if a subject enrolls in another study that requires the administration of experimental therapies (vaccines or medications), he/she may no longer participate in this protocol.
- (Presence of P. falciparum parasitemia in the absence of symptoms at the time of screening is not exclusionary).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Longitudinal Analysis of the B-Cell Immune Response to Plasmodium Falciparum in Mali
This study will examine the immune response to the malaria parasite at the cellular level to better understand why people achieve natural immunity to the parasite only after multiple infections and why immunity diminishes rapidly in the absence of ongoing infection. The results of this study may provide insight into whether and how natural immunity can be improved upon by vaccination.
Healthy people 2-4 and 18-25 years of age who live in the village of Kambila, Mali, may be eligible for this 1-year study. Participants have a small blood sample collected from a vein in the arm and also from two finger pricks at the beginning of the study, then every 2 months for 6 months and at the end of the study (for a total of five samples). People who become ill with malaria are evaluated and treated by a physician. Those recovering from their first episode of malaria during the study period have another blood sample collection and two finger pricks (bringing to six the total number of samples collected).
Read the detailed description
Malaria remains an important public health threat, responsible for over one million deaths annually, the majority among African children. The development of a safe and effective vaccine is widely regarded as a crucial step forward in the control of this disease. However, vaccines tested in clinical trials to date have resulted in very short-lived protection at best. This appears to mirror the kinetics of naturally acquired immunity to Plasmodium falciparum, in that multiple infections are required over many years before clinical immunity is achieved, and then appears to diminish relatively rapidly in the absence of ongoing infection. The mechanisms underlying the delayed acquisition and presumably rapid loss of humoral immunity are poorly understood. A more detailed understanding of these processes on the cellular level may provide insight into whether and how natural immunity can be improved upon by vaccination. This longitudinal cohort study in a P. falciparum endemic village of Mali proposes to test the hypothesis that resistance to malaria is associated with acquisition of P. falciparum specific memory B cells. The 52 week study will cover an entire malaria transmission season and will enroll 224 healthy persons ages 2 to 10 and 18 to 25. After informed consent is obtained from the participant, or the participant's parent or guardian, an age appropriate volume of venous blood will be drawn at baseline, and at 2, 4, 6, and 12 months thereafter; and serum and peripheral blood mononuclear cells (PBMC) will be frozen and stored. One convalescent blood sample per participant will also be drawn within two weeks of their first symptomatic P. falciparum infection. Clinical data, including the frequency and severity of malaria infections, will be collected during the study period by passive surveillance. After 52 weeks, serum and PBMC will be thawed and analyzed to determine antibody titers to malaria antigens and to enumerate relevant B cell subpopulations, including total and antigen-specific naive, memory, and plasma cells by ELISPOT assays and flow cytometry.
- Conditions
- Malaria
- Keywords
- Immunity, Memory, ELISPOT, Malaria, Prospective
- Medical subject headings
- Malaria
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2006 (estimated)
- Study start17 Apr 2006
- Study completion23 Jan 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for MalariaStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Enrolment
- 237 participants (actual)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Investigators
- Peter D Crompton, M.D., Principal investigator, National Institute of Allergy and Infectious Diseases (NIAID)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00346346
- Sponsor's protocol ID
- 999906147
- Other IDs
- 06-I-N147
- Status last verified
- 23 Jan 2013
- First submitted
- 28 Jun 2006
- Last updated
- 5 Dec 2019
- Results posted
- No
Publications
Achidi EA, Perlmann H, Salimonu LS, Perlmann P, Walker O, Asuzu MC. A longitudinal study of seroreactivities to Plasmodium falciparum antigens in Nigerian infants during their first year of life. Acta Trop. 1995 May;59(2):173-83. doi: 10.1016/0001-706x(95)00076-q.
PubMed 7676908ALLISON AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J. 1954 Feb 6;1(4857):290-4. doi: 10.1136/bmj.1.4857.290. No abstract available.
PubMed 13115700ALLISON AC. Glucose-6-phosphate dehydrogenase deficiency in red blood cells of East Africans. Nature. 1960 May 14;186:531-2. doi: 10.1038/186531a0. No abstract available.
PubMed 13792821
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Longitudinal Analysis of the B-Cell Immune Response to Plasmodium Falciparum in Mali
- ClinicalTrials.gov ID
- NCT00346346
- Acronym / sponsor ID
- 999906147
- Conditions
- Malaria
- Keywords
- Immunity, Memory, ELISPOT, Malaria, Prospective
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 237 participants (actual)
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Study start
- 17 Apr 2006
- Study completion
- 23 Jan 2013
- First posted
- 29 Jun 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will examine the immune response to the malaria parasite at the cellular level to better understand why people achieve natural immunity to the parasite only after multiple infections and why immunity diminishes rapidly in the absence of ongoing infection. The results of this study may provide insight into whether and how natural immunity can be improved upon by vaccination.
Healthy people 2-4 and 18-25 years of age who live in the village of Kambila, Mali, may be eligible for this 1-year study. Participants have a small blood sample collected from a vein in the arm and also from two finger pricks at the beginning of the study, then every 2 months for 6 months and at the end of the study (for a total of five samples). People who become ill with malaria are evaluated and treated by a physician. Those recovering from their first episode of malaria during the study period have another blood sample collection and two finger pricks (bringing to six the total number of samples collected).
Detailed description
Malaria remains an important public health threat, responsible for over one million deaths annually, the majority among African children. The development of a safe and effective vaccine is widely regarded as a crucial step forward in the control of this disease. However, vaccines tested in clinical trials to date have resulted in very short-lived protection at best. This appears to mirror the kinetics of naturally acquired immunity to Plasmodium falciparum, in that multiple infections are required over many years before clinical immunity is achieved, and then appears to diminish relatively rapidly in the absence of ongoing infection. The mechanisms underlying the delayed acquisition and presumably rapid loss of humoral immunity are poorly understood. A more detailed understanding of these processes on the cellular level may provide insight into whether and how natural immunity can be improved upon by vaccination. This longitudinal cohort study in a P. falciparum endemic village of Mali proposes to test the hypothesis that resistance to malaria is associated with acquisition of P. falciparum specific memory B cells. The 52 week study will cover an entire malaria transmission season and will enroll 224 healthy persons ages 2 to 10 and 18 to 25. After informed consent is obtained from the participant, or the participant's parent or guardian, an age appropriate volume of venous blood will be drawn at baseline, and at 2, 4, 6, and 12 months thereafter; and serum and peripheral blood mononuclear cells (PBMC) will be frozen and stored. One convalescent blood sample per participant will also be drawn within two weeks of their first symptomatic P. falciparum infection. Clinical data, including the frequency and severity of malaria infections, will be collected during the study period by passive surveillance. After 52 weeks, serum and PBMC will be thawed and analyzed to determine antibody titers to malaria antigens and to enumerate relevant B cell subpopulations, including total and antigen-specific naive, memory, and plasma cells by ELISPOT assays and flow cytometry.
Study design
Who may qualify
- Ages
- 2 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
Key exclusion criteria (7 listed)
- Active bleeding or hematocrit less than or equal to 15 % (for both children and adults).
- Fever greater than 38 degrees C, or systemic illness at enrollment.
- Currently using anti-malarial medications.
- The following two exclusion items may not have occurred in the last 30 days: participation in a vaccine or drug trial, or use of corticosteroid or other immunosuppressive drugs.
- Current pregnancy or a plan to become pregnant during the one year study period. Pregnancy status will be determined at enrollment by urine dipstick, and at subsequent time points by self-report only.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2019.
- Background: PubMed 7676908Achidi EA, Perlmann H, Salimonu LS, Perlmann P, Walker O, Asuzu MC. A longitudinal study of seroreactivities to Plasmodium falciparum antigens in Nigerian infants during their first year of life. Acta Trop. 1995 May;59(2):173-83. doi: 10.1016/0001-706x(95)00076-q.
- Background: PubMed 13115700ALLISON AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J. 1954 Feb 6;1(4857):290-4. doi: 10.1136/bmj.1.4857.290. No abstract available.
- Background: PubMed 13792821ALLISON AC. Glucose-6-phosphate dehydrogenase deficiency in red blood cells of East Africans. Nature. 1960 May 14;186:531-2. doi: 10.1038/186531a0. No abstract available.
Related trials for Malaria
Active, not recruitingObservational study
Trajectories and Mechanisms of Recovery From Malaria: An Observational Study
Malaria
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
Recruiting
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
Iron Deficiencies
RecruitingObservational study
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria
RecruitingPhase 1
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Malaria Falciparum
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter D Crompton, M.D. principal investigator
National Institute of Allergy and Infectious Diseases (NIAID)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Malaria, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in Mali.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mali. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00346346, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2019.